PRDX5 · Western blot design guide

PRDX5 Western Blot Planning Guide

Plan a PRDX5 Western blot around the catalog-observed 22.1 kDa band, image-backed PB9384 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for PRDX5 (PRDX5): expected band 22.1 kDa, antibody PB9384, and guide-derived SDS-PAGE protocol steps
PRDX5 Western blot protocol sheet — expected band 22.1 kDa, antibody PB9384, controls and PMC citations. Open the full PRDX5 WB guide →

PRDX5 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 22.1 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Cerebellum
Negative control ⓘ Adipose tissue
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 22.1 kDa
ⓘ Localization Mitochondrion / Cytoplasm
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated PRDX5 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAppendix
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, short transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPB9384 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected PRDX5 Western Blot Band Size?

Use the product-observed 22.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
22.1 kDaMatches the authoritative product WB observation.
22.1 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected PRDX5 appearancePlan around 22.1 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band22.1 kDa; use this as the primary experimental expectation.
Calculated mass22.1 kDa from UniProt P30044; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PB9384.
Why is my band missing or off?
SituationLikely causeNext action
22.1 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for PRDX5 Western blot

🧪Use Cerebellum as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Cerebellum (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for PRDX5

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Cerebellum Reported tissue cells High Protein (HPA) HPA →
Fallopian tube Reported tissue cells High Protein (HPA) HPA →
Colon Reported tissue cells High Protein (HPA) HPA →
Appendix Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Adipose tissue Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced PRDX5 Western Blot Tips

Deeper troubleshooting and optimisation questions for PRDX5, answered from its protein features.

Which band should guide the blot?
Use 22.1 kDa, the observation attached to the authoritative PB9384 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 22.1 kDa expectation.
Which positive control should I start with?
Start with Cerebellum, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PRDX5 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9384 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

PRDX5 Western Blot Reagents

Human/Mouse/Rat-reactive PRDX5 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for PRDX5 using PB9384; observed band 22.1 kDa
Anti-Peroxiredoxin 5/PRDX5 Antibody Picoband®
Cat # PB9384
Real WB data Western blot validation image for PRDX5 using PA1838; observed band 22.1 kDa
Anti-Peroxiredoxin 5/PRDX5 Antibody Picoband®
Cat # PA1838

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P30044
  2. Human Protein Atlas — PRDX5
  3. PB9384 product record
  4. PMC5400646 — Quantitative proteomic analysis of gastric cancer tissue reveals novel proteins in platelet-derived growth factor b signaling pathway (Oncotarget, 2017)